China Resources Double Crane (600062.SH) subsidiary Pruvabalin extended-release tablets have completed Phase III clinical trials.

According to a news report from Zhitong Finance APP, China Resources Double Crane (600062.SH) announced that its wholly-owned subsidiary China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd. (referred to as "Double Crane Limin") has completed the registration and public announcement of the Phase III clinical trial of Pregabalin sustained-release tablets.